BCL2 and cancer: Of interest, our case-control study included only one triple negative BC, indicating that a triple negative status was not a confounding variable in our study, and that p53, cathepsin D and Bcl-2 are efficient aggressiveness determinants in BC across currently categorized cancer subgroups.